ArticleRespiratory research2021

RORγt inhibitors block both IL-17 and IL-22 conferring a potential advantage over anti-IL-17 alone to treat severe asthma.

David Lamb et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.